Keros Therapeutics (KROS) Operating Leases (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Operating Leases for 7 consecutive years, with $16.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Operating Leases changed 0.0% year-over-year to $16.9 million, compared with a TTM value of $16.9 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $16.9 million, changed 0.0% over the prior year.
- Operating Leases was $16.9 million for Q4 2025 at Keros Therapeutics, up from $15.1 million in the prior quarter.
- Across five years, Operating Leases topped out at $17.4 million in Q3 2024 and bottomed at $231000.0 in Q4 2021.
- Average Operating Leases over 5 years is $10.7 million, with a median of $13.4 million recorded in 2023.
- The sharpest move saw Operating Leases tumbled 65.03% in 2021, then surged 5445.89% in 2022.
- Year by year, Operating Leases stood at $231000.0 in 2021, then soared by 5445.89% to $12.8 million in 2022, then increased by 4.9% to $13.4 million in 2023, then grew by 25.63% to $16.9 million in 2024, then changed by 0.0% to $16.9 million in 2025.
- Business Quant data shows Operating Leases for KROS at $16.9 million in Q4 2025, $15.1 million in Q3 2025, and $15.7 million in Q2 2025.